Survival First: Three Chinese Biotechs Downsize R&D Amid Funding Downturn

 
• By Dexter Jie Yan

A clutch of Chinese biopharma firms, including I-Mab, Lepu and Clover, are having second thoughts on some of their clinical development programs to conserve cash amid a funding squeeze.

R&D cuts
Some Chinese biotechs start to save for a rainy day to prevent cashflow • Source: Shutterstock

More from China

More from Focus On Asia